12 results on '"Merino Ochoa O"'
Number of results to display per page
Search Results
2. P262 Effectiveness and safety of ustekinumab in elderly patients: Real world evidence from ENEIDA registry
- Author
-
Casas Deza, D, primary, Lamuela Calvo, L J, additional, Arbonés Mainar, J M, additional, Ricart, E, additional, Gisbert, J P, additional, Rivero Tirado, M, additional, Sanchez Rodríguez, E, additional, Sicilia, B, additional, Gutierrez Casbas, A, additional, Merino Ochoa, O, additional, Márquez, L, additional, Laredo de la Torre, V, additional, Martin Arranz, M D, additional, Lopez Serrano, P, additional, Riestra Menéndez, S, additional, Gonzalez Muñoza, C, additional, de Castro Parga, L, additional, Calvo Moya, M, additional, Garcia Alonso, J, additional, Esteve, M, additional, Iborra Colomino, M, additional, Dura Gil, M, additional, Barreiro de Acosta, M, additional, Lorente Poyatos, R, additional, Manceñido, N, additional, Caballo, B, additional, Calafat, M, additional, Rodríguez Lago, I, additional, Guardiola Capo, J, additional, Morales Alvarado, V J, additional, Tardillo, C, additional, Bujanda, L, additional, Muñoz Nuñez, J F, additional, Ber Nieto, Y, additional, Bermejo, F, additional, Chaparro, M, additional, Almela, P, additional, Navarro, M, additional, Domènech, E, additional, and García López, S, additional
- Published
- 2021
- Full Text
- View/download PDF
3. P263 Influence of Crohn′s Disease phenotype in the retention rate of ustekinumab treatment: SUSTAIN Study
- Author
-
Chaparro, M, primary, Bastón Rey, I, additional, Fernández-Salgado, E, additional, González García, J, additional, Ramos, L, additional, Diz-Lois Palomares, M T, additional, Argüelles, F, additional, Iglesias Flores, E, additional, Cabelo, M, additional, Rubio Iturria, S, additional, Núñez Ortiz, A, additional, Charro, M, additional, Ginard, D, additional, Dueñas Sadornil, C, additional, Merino Ochoa, O, additional, David, B, additional, Iyo, E, additional, Gutiérrez Casbas, A, additional, Ramírez de la Piscina, P, additional, Boscá-Watts, M M, additional, Arroyo, M, additional, García, M J, additional, Hinojosa, E, additional, Gordillo, J, additional, Martínez Montiel, P, additional, Velayos Jiménez, B, additional, Quílez Ivorra, C, additional, Vázque morón, J M, additional, Huguet, J M, additional, González Lama, Y, additional, Muñagorri Santos, A I, additional, Amo, V M, additional, Martín Arranz, M D, additional, Bermejo, F, additional, Martínez Cadilla, J, additional, Fradejas Salazar, P, additional, Novella, C, additional, Vispo, E, additional, Barreiro-de Acosta, M, additional, and Gisbert, J P, additional
- Published
- 2021
- Full Text
- View/download PDF
4. P509 Influence of concomitant immunosuppresives in retention rate in Crohn′s Disease patients under ustekinumab in the SUSTAIN Study
- Author
-
Chaparro, M, primary, Bastón Rey, I, additional, Fernández-Salgado, E, additional, González García, J, additional, Ramos, L, additional, Diz-Lois Palomares, M T, additional, Argüelles, F, additional, Iglesias Flores, E, additional, Cabello, M, additional, Rubio Iturria, S, additional, Núñez Ortiz, A, additional, Charro, M, additional, Ginard, D, additional, Dueñas Sadornil, C, additional, Merino Ochoa, O, additional, Busquets, D, additional, Iyo, E, additional, Gutiérrez Casbas, A, additional, Ramírez de la Piscina, P, additional, Boscá-Watts, M M, additional, Arroyo, M, additional, García, M J, additional, Hinojosa, E, additional, Gordillo, J, additional, Martínez Montiel, P, additional, Velayos Jiménez, B, additional, Quílez Ivorra, C, additional, Vázquez Morón, J M, additional, Huguet, J M, additional, González Lama, Y, additional, Muñagorri Santos, A I, additional, Amo, V M, additional, Martín Arranz, M D, additional, Bermejo, F, additional, Martínez Cadilla, J, additional, Fradejas Salazar, P, additional, Novella, C, additional, Vispo, E, additional, Barreiro-de Acosta, M, additional, and Gisbert, J P, additional
- Published
- 2021
- Full Text
- View/download PDF
5. Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry
- Author
-
Chaparro, M, Garre, A, Mesonero, F, Rodriguez, C, Barreiro-de Acosta, M, Martinez-Cadilla, J, Arroyo, MT, Mancenido, N, Sierra-Ausin, M, Vera-Mendoza, I, Casanova, MJ, Nos, P, Gonzalez-Munoza, C, Martinez, T, Bosca-Watts, M, Busquets, D, Calafat, M, Girona, E, Llao, J, Martin-Arranz, MD, Piqueras, M, Ramos, L, Suis, G, Bermejo, F, Carbajo, AY, Casas-Deza, D, Fernandez-Clotet, A, Garcia, MJ, Ginard, D, Gutierrez-Casbas, A, Hernandez-Villalba, L, Lucendo, AJ, Marquez, L, Merino-Ochoa, O, Rancel, FJ, Taxonera, C, Sanroman, AL, Rubio, S, Domenech, E, and Gisbert, JP
- Published
- 2020
6. OP29 Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry
- Author
-
Chaparro, M, primary, Garre, A, additional, Mesonero, F, additional, Rodríguez, C, additional, Barreiro-de Acosta, M, additional, Martínez-Cadilla, J, additional, Arroyo, M T, additional, Manceñido, N, additional, Sierra-Ausín, M, additional, Vera-Mendoza, I, additional, Casanova, M J, additional, Nos, P, additional, González-Muñoza, C, additional, Martínez, T, additional, Boscá-Watts, M, additional, Busquets, D, additional, Calafat, M, additional, Girona, E, additional, Llaó, J, additional, Martín-Arranz, M D, additional, Piqueras, M, additional, Ramos, L, additional, Suis, G, additional, Bermejo, F, additional, Carbajo, A Y, additional, Casas-Deza, D, additional, Fernández-Clotet, A, additional, García, M J, additional, Ginard, D, additional, Gutiérrez-Casbas, A, additional, Hernández-Villalba, L, additional, Lucendo, A J, additional, Márquez, L, additional, Merino-Ochoa, O, additional, Rancel, F J, additional, Taxonera, C, additional, López Sanromán, A, additional, Rubio, S, additional, Domènech, E, additional, and Gisbert, J P, additional
- Published
- 2020
- Full Text
- View/download PDF
7. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
- Author
-
Chaparro, María, primary, Donday, María G., additional, Barreiro-de Acosta, Manuel, additional, Domènech, Eugeni, additional, Esteve, María, additional, García-Sánchez, Valle, additional, Nos, Pilar, additional, Panés, Julián, additional, Martínez, Concepción, additional, Gisbert, Javier P., additional, Abad, F., additional, Aguas Peris, M., additional, Agüero Tejado, E., additional, Alba, C., additional, Albert, M., additional, Alemán, H., additional, Algaba, A., additional, Alonso Abreu, I., additional, Amador, M.P., additional, Amat, M., additional, Angueira, T., additional, Arajol, C., additional, Arias-González, L., additional, Arrondo Velasco, A., additional, Baldán, M., additional, Bardán García, B., additional, Bargalló García, A., additional, Barreiro de Acosta, M., additional, Barrio Andrés, J., additional, Bastida Paz, G., additional, Bastón Rey, I., additional, Batista, L., additional, Bellver Martínez, M., additional, Beltrán Niclós, B., additional, Benítez, J.M., additional, Ber Nieto, Y., additional, Bermejo, F., additional, Bernardo, D., additional, Blázquez Gómez, I., additional, Bouhmidi Assakali, A., additional, Busquets Casals, D., additional, Cabriada Nuño, J.L., additional, Calvet Calvo, X., additional, Calvo Hernández, M.V., additional, Calvo, M., additional, Camps, B., additional, Carbajo, A.Y., additional, Cardona Peitx, G., additional, Caro-Patón, T., additional, Carrillo Palau, M., additional, Carrión Bolorino, S., additional, Casanova, M.J., additional, Casellas Valdé, J.A., additional, Castaño García, A., additional, Castro Senosiain, B., additional, Ceballos, D., additional, Cerrillo, E., additional, Chacón Martínez, S., additional, Consuelo Cañete Pizarro, F., additional, de Castro Parga, M.L., additional, de Miguel, M., additional, de Francisco García, R., additional, de la Cruz Ramírez, M.D., additional, del Hoyo Francisco, J., additional, Delgado Guillena, P., additional, Desongles Corrales, T., additional, Echarri Piudo, A., additional, Espino Paisan, E., additional, Espona Quer, M., additional, Fernández Pordomingo, A., additional, Fernández Forcelledo, J.L., additional, Fernández-Tomé, S., additional, Ferreiro Iglesias, R., additional, Ferrer Bradley, I., additional, Ferrer, A., additional, Figueroa, A., additional, Gallach Montero, M., additional, García Iglesias, P., additional, García García-Lezcún, C., additional, García Ramírez, L., additional, García García, M.J., additional, García-Bosh, O., additional, Garre, A., additional, Giménez Poderós, T., additional, Gómez Irwin, L., additional, Gómez Pastrana, B., additional, Gómez Delgado, E., additional, González Lama, Y., additional, Gracia García, Á., additional, Gracia García, B., additional, Guardiola, J., additional, Guerra, I., additional, Guerra, E., additional, Guillot, V., additional, Gustmancher Saiz, S., additional, Gutiérrez Casbas, A., additional, Hernández Ramírez, V., additional, Hernando Verdugo, M.M., additional, Hernández Muniesa, B., additional, Hernanz Chaves, R., additional, Herrera Justiniano, J.M., additional, Hinojosa del Val, J, additional, Ibáñez Feijoo, S, additional, Iborra Colomino, M, additional, Iglesias Flores, E, additional, Izquierdo García, E., additional, Sampedro González, M J, additional, Lucendo, A J., additional, Jiménez García, N, additional, Leo Carnerero, E., additional, Loizaga Díaz, I., additional, López de Torre Querejazu, A, additional, López Sánchez, P, additional, Luis Parras, J, additional, Maia Boscá, M, additional, Mañosa, M, additional, Marín Pedrosa, S, additional, Marín, A, additional, Marinero, Á, additional, Marín-Jiménez, I, additional, Márquez Mosquera, L, additional, Márquez Galán, JL, additional, Martín Arranz, E, additional, Martín Arranz, MD, additional, Martínez Cadilla, J, additional, Martínez Sesmero, JM, additional, Martínez Sánchez, B, additional, Matallana, V, additional, Mateos Hernández, MI, additional, McNicholl, AG, additional, Mejuto Fernández, R, additional, Melcarne, L, additional, Menchén, L, additional, Méndez-Castrillón Rodríguez, J, additional, Merino Ochoa, O, additional, Mínguez, M, additional, Molas Ferrer, G, additional, Montoro Huguet, M, additional, Montserrat Torres, A, additional, Mora, F, additional, Moraleja Yudego, I, additional, Morales Alvarado, VJ, additional, Morales Martínez, L, additional, Morell, A, additional, Motos García, C, additional, Muñoz Alonso, F, additional, Muñoz Villafranca, MC, additional, Muñoz, JE, additional, Mur, A, additional, Nantes, Ó, additional, Navarro, P, additional, Navarro- Llavat, M, additional, Nos Mateu, P, additional, Núñez Alonso, A, additional, Núñez Ortiz, A, additional, Olivares, D, additional, Ollero Pena, V, additional, Orobitg, J, additional, Ortega, L, additional, Ortiz de Zárate, J, additional, Pallarés Manrique, H, additional, Paradela Carreiro, A, additional, Peral Ballester, L, additional, Pereira Bueno, S, additional, Pérez Martínez, I, additional, Pineda Mariño, JR, additional, Piñero Pérez, C, additional, Planas Giner, A, additional, Plaza Santos, MR, additional, Ponferrada Díaz, Á, additional, Poza Cardón, J, additional, Prieto Vicente, V, additional, Puchades, L, additional, Ramos López, L, additional, Redondo, S, additional, Riestra Menéndez, S, additional, Rivero Tirado, M, additional, Rodríguez Lago, I, additional, Rodríguez Gutiérrez, C, additional, Rodríguez, E, additional, Romero Izquierdo, S, additional, Rubio Iturria, S, additional, Ruiz Antorán, MB, additional, Ruiz, A, additional, Salazar, LF, additional, Sánchez Ulayar, A, additional, Sánchez Gómez, E, additional, Sánchez, C, additional, Sangrador, C, additional, Serra, K, additional, Spicakova, K, additional, Suárez Ferrer, C, additional, Talavera Fabuel, A, additional, Taxonera, C, additional, Tordera, M, additional, Torrella Cortés, E, additional, Tosca, J, additional, Trigo Salado, C, additional, Uriarte Estefanía, F, additional, Van Domselaar, M, additional, Vázquez Morón, JM, additional, Ventura López, P, additional, Vera, M, additional, Vicuña Arregui, M, additional, Villoria Ferrer, A, additional, Virgós Aller, T, additional, and Yáñez Feria, D, additional
- Published
- 2019
- Full Text
- View/download PDF
8. The Risk of Developing Disabling Crohn's Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making.
- Author
-
Bastida Paz G, Merino Ochoa O, Aguas Peris M, Barreiro-de Acosta M, Zabana Y, Ginard Vicens D, Ceballos Santos D, Muñoz Núñez F, Monfort I Miquel D, Catalán-Serra I, García Sánchez V, Loras Alastruey C, Lucendo Villarín A, Huguet JM, de la Coba Ortiz C, Aldeguer Manté X, Palau Canós A, Domènech Morral E, and Nos P
- Subjects
- Humans, Adult, Retrospective Studies, Clinical Decision Rules, Risk Factors, Steroids therapeutic use, Decision Making, Crohn Disease diagnosis, Crohn Disease epidemiology, Crohn Disease complications
- Abstract
Background: Crohn's disease (CD) is characterized by the development of complications over the course of the disease. It is crucial to identify predictive factors of disabling disease, in order to target patients for early intervention. We evaluated risk factors of disabling CD and developed a prognostic model., Methods: In total, 511 CD patients were retrospectively analyzed. Univariate and multivariate logistic regression analyses were used to identify demographic, clinical, and biological risk factors. A predictive nomogram model was developed in a subgroup of patients with noncomplicated CD (inflammatory pattern and no perianal disease)., Results: The rate of disabling CD within 5 years after diagnosis was 74.6%. Disabling disease was associated with gender, location of disease, requirement of steroids for the first flare, and perianal lesions. In the subgroup of patients (310) with noncomplicated CD, the rate of disabling CD was 80%. In the multivariate analysis age at onset <40 years (OR = 3.46, 95% confidence interval [CI] = 1.52-7.90), extensive disease (L3/L4) (OR = 2.67, 95% CI = 1.18-6.06), smoking habit (OR = 2.09, 95% CI = 1.03-4.27), requirement of steroids at the first flare (OR = 2.20, 95% CI = 1.09-4.45), and albumin (OR = 0.59, 95% CI = 0.36-0.96) were associated with development of disabling disease. The developed predictive nomogram based on these factors presented good discrimination, with an area under the receiver operating characteristic curve of 0.723 (95% CI: 0.670-0.830)., Conclusion: We identified predictive factors of disabling CD and developed an easy-to-use prognostic model that may be used in clinical practice to help identify patients at high risk and address treatment effectively., (© 2023 S. Karger AG, Basel.)
- Published
- 2023
- Full Text
- View/download PDF
9. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
- Author
-
Chaparro M, Baston-Rey I, Fernández-Salgado E, González García J, Ramos L, Diz-Lois Palomares MT, Argüelles-Arias F, Iglesias Flores E, Cabello M, Rubio Iturria S, Núñez Ortiz A, Charro M, Ginard D, Dueñas Sadornil C, Merino Ochoa O, Busquets D, Iyo E, Gutiérrez Casbas A, Ramírez de la Piscina P, Boscá-Watts MM, Arroyo M, García MJ, Hinojosa E, Gordillo J, Martínez Montiel P, Velayos Jiménez B, Quílez Ivorra C, Vázquez Morón JM, María Huguet J, González-Lama Y, Muñagorri Santos AI, Amo VM, Martín-Arranz MD, Bermejo F, Martínez Cadilla J, Rubín de Célix C, Fradejas Salazar P, San Román AL, Jiménez N, García López S, Figuerola A, Jiménez I, Martínez Cerezo FJ, Taxonera C, Varela P, de Francisco R, Monfort D, Molina Arriero G, Hernández Camba A, García-Alonso FJ, Van Domselaar M, Pajares Villarroya R, Núñez A, Rodríguez Moranta F, Marín-Jiménez I, Robles Alonso V, Martín Rodríguez MDM, Camo-Monterde P, García Tercero I, Navarro Llavat M, Arias García L, Hervías Cruz D, Sulleiro S, Novella C, Vispo E, Barreiro-de Acosta M, and Gisbert JP
- Subjects
- Humans, Retrospective Studies, Remission Induction, Immunosuppressive Agents therapeutic use, Treatment Outcome, Ustekinumab therapeutic use, Crohn Disease drug therapy
- Abstract
Background: Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn's disease (CD) patients in real-world clinical practice., Methods: A retrospective, multicentre study was conducted in Spain in patients with active CD who had received ≥1 intravenous dose of ustekinumab for ≥6 months. Primary outcome was ustekinumab retention rate; secondary outcomes were to identify predictive factors for drug retention, short-term remission (week 16), loss of response and predictive factors for short-term efficacy and loss of response, and ustekinumab safety., Results: A total of 463 patients were included. Mean baseline Harvey-Bradshaw Index was 8.4. A total of 447 (96.5%) patients had received prior biologic therapy, 141 (30.5%) of whom had received ≥3 agents. In addition, 35.2% received concomitant immunosuppressants, and 47.1% had ≥1 abdominal surgery. At week 16, 56% had remission, 70% had response, and 26.1% required dose escalation or intensification; of these, 24.8% did not subsequently reduce dose. After a median follow-up of 15 months, 356 (77%) patients continued treatment. The incidence rate of ustekinumab discontinuation was 18% per patient-year of follow-up. Previous intestinal surgery and concomitant steroid treatment were associated with higher risk of ustekinumab discontinuation, while a maintenance schedule every 12 weeks had a lower risk; neither concomitant immunosuppressants nor the number of previous biologics were associated with ustekinumab discontinuation risk. Fifty adverse events were reported in 39 (8.4%) patients; 4 of them were severe (2 infections, 1 malignancy, and 1 fever)., Conclusions: Ustekinumab is effective and safe as short- and long-term treatment in a refractory cohort of CD patients in real-world clinical practice., (© 2022 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.)
- Published
- 2022
- Full Text
- View/download PDF
10. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab.
- Author
-
Chaparro M, Baston-Rey I, Fernández Salgado E, González García J, Ramos L, Diz-Lois Palomares MT, Argüelles-Arias F, Iglesias Flores E, Cabello M, Rubio Iturria S, Núñez Ortiz A, Charro M, Ginard D, Dueñas Sadornil C, Merino Ochoa O, Busquets D, Iyo E, Gutiérrez Casbas A, Ramírez de la Piscina P, Boscá-Watts MM, Arroyo M, García MJ, Hinojosa E, Gordillo J, Martínez Montiel P, Velayos Jiménez B, Quílez Ivorra C, Vázquez Morón JM, Huguet JM, González-Lama Y, Muñagorri Santos AI, Amo VM, Martín Arranz MD, Bermejo F, Martínez Cadilla J, Rubín de Célix C, Fradejas Salazar P, López San Román A, Jiménez N, García-López S, Figuerola A, Jiménez I, Martínez Cerezo FJ, Taxonera C, Varela P, de Francisco R, Monfort D, Molina Arriero G, Hernández-Camba A, García Alonso FJ, Van Domselaar M, Pajares-Villarroya R, Núñez A, Rodríguez Moranta F, Marín-Jiménez I, Robles Alonso V, Martín Rodríguez MDM, Camo-Monterde P, García Tercero I, Navarro-Llavat M, García LA, Hervías Cruz D, Kloss S, Passey A, Novella C, Vispo E, Barreiro-de Acosta M, and Gisbert JP
- Abstract
Ustekinumab has shown efficacy in Crohn's Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the therapeutic paradigm of CD and generate hypotheses for future trials. The objective of this analysis was to determine whether baseline patient characteristics are predictive of remission and the drug durability of ustekinumab, and whether its positioning with respect to prior use of biologics has a significant effect after correcting for disease severity and phenotype at baseline using interpretable machine learning. Patients' data from SUSTAIN, a retrospective multicenter single-arm cohort study, were used. Disease phenotype, baseline laboratory data, and prior treatment characteristics were documented. Clinical remission was defined as the Harvey Bradshaw Index ≤ 4 and was tracked longitudinally. Drug durability was defined as the time until a patient discontinued treatment. A total of 439 participants from 60 centers were included and a total of 20 baseline covariates considered. Less exposure to previous biologics had a positive effect on remission, even after controlling for baseline disease severity using a non-linear, additive, multivariable model. Additionally, age, body mass index, and fecal calprotectin at baseline were found to be statistically significant as independent negative risk factors for both remission and drug survival, with further risk factors identified for remission.
- Published
- 2022
- Full Text
- View/download PDF
11. Acute gastric dilatation in a patient with anorexia nervosa.
- Author
-
Roa Esparza Í, González Ocio J, and Merino Ochoa O
- Subjects
- Acute Disease, Adult, Female, Humans, Anorexia Nervosa complications, Bulimia, Gastric Dilatation diagnostic imaging, Gastric Dilatation etiology
- Abstract
A 43-year-old female with a history of anorexia nervosa presented to our hospital with diffuse abdominal pain and distension after a binge eating episode. Vital signs and routine laboratory test results were unremarkable, except for a slightly elevated white blood cell count (14.5 x 109/l). Abdominal radiography and computed tomography (CT) revealed a massively dilated stomach, with a craniocaudal measurement of 37 cm.
- Published
- 2021
- Full Text
- View/download PDF
12. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
- Author
-
Chaparro M, Garre A, Mesonero F, Rodríguez C, Barreiro-de Acosta M, Martínez-Cadilla J, Arroyo MT, Manceñido N, Sierra-Ausín M, Vera-Mendoza I, Casanova MJ, Nos P, González-Muñoza C, Martínez T, Boscá-Watts M, Calafat M, Busquets D, Girona E, Llaó J, Martín-Arranz MD, Piqueras M, Ramos L, Surís G, Bermejo F, Carbajo AY, Casas-Deza D, Fernández-Clotet A, García MJ, Ginard D, Gutiérrez-Casbas A, Hernández L, Lucendo AJ, Márquez L, Merino-Ochoa O, Rancel FJ, Taxonera C, López Sanromán A, Rubio S, Domènech E, and Gisbert JP
- Subjects
- Dose-Response Relationship, Drug, Drug Monitoring methods, Female, Humans, Male, Middle Aged, Patient Acuity, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Recurrence, Registries statistics & numerical data, Spain epidemiology, Treatment Outcome, Colitis, Ulcerative diagnosis, Colitis, Ulcerative drug therapy, Colitis, Ulcerative epidemiology, Piperidines administration & dosage, Piperidines adverse effects, Pyrimidines administration & dosage, Pyrimidines adverse effects, Remission Induction methods
- Abstract
Aim: To evaluate the effectiveness and safety of tofacitinib in ulcerative colitis [UC] in real life., Methods: Patients from the prospectively maintained ENEIDA registry and treated with tofacitinib due to active UC were included. Clinical activity and effectiveness were defined based on Partial Mayo Score [PMS]. Short-term response/remission was assessed at Weeks 4, 8, and 16., Results: A total of 113 patients were included. They were exposed to tofacitinib for a median time of 44 weeks. Response and remission at Week 8 were 60% and 31%, respectively. In multivariate analysis, higher PMS at Week 4 (odds ratio [OR] = 0].2; 95% confidence interval [CI] = 0].1-0.4) was the only variable associated with lower likelihood of achieving remission at Week 8. Higher PMS at Week 4 [OR = 0.5; 95% CI = 0.3-0.7] and higher PMS at Week 8 [OR = 0.2; 95% CI = 0.1-0.5] were associated with lower probability of achieving remission at Week 16. A total of 45 patients [40%] discontinued tofacitinib over time. Higher PMS at Week 8 was the only factor associated with higher tofacitinib discontinuation [hazard ratio = 1.5; 95% CI = 1.3-1.6]. A total of 34 patients had remission at Week 8; of these, 65% had relapsed 52 weeks after achieving remission; the dose was increased to 10 mg/12 h in nine patients, and five of them reached remission again. Seventeen patients had adverse events., Conclusions: Tofacitinib is effective and safe in UC patients in real practice, even in a highly refractory cohort. A relevant proportion of patients discontinue the drug over time, mainly due to primary failure., (© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.